相似文献
1
Size matters in non-canonical inflammasome activation and cell-mediated immunity.
Cell Rep Med. 2023 Jan 17;4(1):100904. doi: 10.1016/j.xcrm.2022.100904.
2
The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants.
Eur J Immunol. 2010 Mar;40(3):634-8. doi: 10.1002/eji.200940172.
3
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
J Biol Chem. 2016 Jan 15;291(3):1123-36. doi: 10.1074/jbc.M115.683011. Epub 2015 Nov 10.
4
NLRP3 inflammasome activation and cytotoxicity induced by particulate adjuvants.
Methods Mol Biol. 2013;1040:41-63. doi: 10.1007/978-1-62703-523-1_5.
5
K⁺ drops tilt the NLRP3 inflammasome.
Immunity. 2013 Jun 27;38(6):1085-8. doi: 10.1016/j.immuni.2013.06.001.
6
Structural mechanisms in NLR inflammasome signaling.
Curr Opin Struct Biol. 2014 Dec;29:17-25. doi: 10.1016/j.sbi.2014.08.011. Epub 2014 Sep 15.
7
Regulation of adaptive immunity by the NLRP3 inflammasome.
Int Immunopharmacol. 2011 May;11(5):549-54. doi: 10.1016/j.intimp.2010.11.025. Epub 2010 Nov 27.
8
Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.
J Immunol. 2008 Jul 1;181(1):17-21. doi: 10.4049/jimmunol.181.1.17.
9
Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants.
Immunol Cell Biol. 2014 Jul;92(6):535-42. doi: 10.1038/icb.2014.21. Epub 2014 Apr 1.
10
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.
Vaccine. 2009 May 18;27(23):3013-21. doi: 10.1016/j.vaccine.2009.03.034. Epub 2009 Apr 3.
本文引用的文献
1
Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles.
Cell Rep Med. 2023 Jan 17;4(1):100899. doi: 10.1016/j.xcrm.2022.100899.
2
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines.
Nat Immunol. 2022 Apr;23(4):532-542. doi: 10.1038/s41590-022-01160-y. Epub 2022 Mar 24.
3
Emerging concepts in the science of vaccine adjuvants.
Nat Rev Drug Discov. 2021 Jun;20(6):454-475. doi: 10.1038/s41573-021-00163-y. Epub 2021 Apr 6.
4
Inflammasomes and adaptive immune responses.
Nat Immunol. 2021 Apr;22(4):412-422. doi: 10.1038/s41590-021-00869-6. Epub 2021 Feb 18.
5
Regulation, Activation and Function of Caspase-11 during Health and Disease.
Int J Mol Sci. 2021 Feb 3;22(4):1506. doi: 10.3390/ijms22041506.
6
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11169-74. doi: 10.1073/pnas.1107941108. Epub 2011 Jun 20.
7
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.
Nat Rev Immunol. 2010 Nov;10(11):787-96. doi: 10.1038/nri2868. Epub 2010 Oct 15.
8
The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants.
Eur J Immunol. 2010 Mar;40(3):638-42. doi: 10.1002/eji.200940039.
9
Exploiting lymphatic transport and complement activation in nanoparticle vaccines.
Nat Biotechnol. 2007 Oct;25(10):1159-64. doi: 10.1038/nbt1332. Epub 2007 Sep 16.
10
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.
Science. 2006 Dec 22;314(5807):1936-8. doi: 10.1126/science.1135299.
Zotero 插件